MAIA Pharmaceuticals Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

MAIA Pharmaceuticals General Information

Description

Operator of a special pharmaceutical company intended to market injectable products for unmet medical needs. The company's leading drug candidate Sincalide is an injectable drug used to stimulate gallbladder contraction, enabling heath care practitioners to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 707 State Road
  • Suite 104
  • Princeton, NJ 08540
  • United States
+1 (609)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Corporate Office
  • 707 State Road
  • Suite 104
  • Princeton, NJ 08540
  • United States
+1 (609)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MAIA Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Apr-2020 Completed Out of Business
2. Early Stage VC (Series A) 12-Nov-2014 Completed Startup
1. Corporate 23-Apr-2013 $1.4M $1.4M Completed Startup
To view MAIA Pharmaceuticals’s complete valuation and funding history, request access »

MAIA Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view MAIA Pharmaceuticals’s complete cap table history, request access »

MAIA Pharmaceuticals Patents

MAIA Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260137753-A1 Daptomycin compositions Pending 21-Nov-2024
WO-2026111848-A1 Daptomycin compositions Pending 21-Nov-2024
EP-4701631-A1 Levothyroxine dispersions Pending 28-Apr-2023
US-20260294858-A1 Levothyroxine dispersions Pending 28-Apr-2023
WO-2024224373-A1 Levothyroxine dispersions Inactive 28-Apr-2023 A61K9/0019
To view MAIA Pharmaceuticals’s complete patent history, request access »

MAIA Pharmaceuticals FAQs

  • When was MAIA Pharmaceuticals founded?

    MAIA Pharmaceuticals was founded in 2013.

  • Where is MAIA Pharmaceuticals headquartered?

    MAIA Pharmaceuticals is headquartered in Princeton, NJ.

  • What industry is MAIA Pharmaceuticals in?

    MAIA Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is MAIA Pharmaceuticals a private or public company?

    MAIA Pharmaceuticals is a Private company.

  • What is MAIA Pharmaceuticals’s current revenue?

    The current revenue for MAIA Pharmaceuticals is .

  • How much funding has MAIA Pharmaceuticals raised over time?

    MAIA Pharmaceuticals has raised $2.25M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process